Review:
Proteasome Inhibitors (e.g., Bortezomib)
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
Proteasome inhibitors, such as Bortezomib, are a class of drugs that target the proteasome, a protein complex responsible for degrading unneeded or damaged proteins within cells. By inhibiting the proteasome's activity, these agents disrupt cellular homeostasis, inducing apoptosis especially in rapidly dividing cancer cells. Bortezomib is primarily used in the treatment of multiple myeloma and mantle cell lymphoma, bringing a targeted approach to cancer therapy.
Key Features
- Selective inhibition of the 26S proteasome
- Disrupts protein degradation pathways in cells
- Induces apoptosis in cancer cells
- Administered via intravenous or subcutaneous injection
- Approved for use in multiple myeloma and certain lymphomas
- Potential side effects include peripheral neuropathy, infections, and gastrointestinal issues
Pros
- Effective against certain types of blood cancers such as multiple myeloma
- Provides a targeted therapeutic approach reducing some side effects compared to traditional chemotherapy
- Has improved survival rates and quality of life for some patients
- Once-daily dosing options enhance convenience
Cons
- Can cause significant adverse effects like peripheral neuropathy and fatigue
- Risk of infections due to immune suppression
- Development of resistance over time in some patients
- High cost of therapy